Inhibitors of the enzyme dipeptidyl peptidase-IV (DPP-IV) are a new class of agents for the treatment of type 2 diabetes [1] . DPP-IV is responsible for the rapid inactivation of glucagon-like peptide-1 (GLP-1), reducing its active half-life to only 1-2 min. GLP-1 is an incretin hormone that is released from the gut when food is ingested to augment glucose-stimulated insulin secretion [2] . It exhibits multiple actions that are beneficial for the treatment of type 2 diabetes, including glucose-dependent stimulation of insulin secretion, inhibition of glucagon secretion, delaying gastric emptying, and induction of satiety. In addition, it has the potential to increase beta cell mass by stimulating the differentiation of precursor cells into beta cells and by inhibiting beta cell apoptosis [2] . The beneficial effects of GLP-1 were shown as early as 1992 and have been supported by numerous studies, one of which investigated the effects of a continuous 6-week subcutaneous infusion [3, 4] . GLP-1 therefore offers a novel approach to the treatment of type 2 diabetes, but its positive effects are counterbalanced by the need for continuous infusion. This limitation may be overcome by the development of GLP-1 receptor agonists (GLP-1 mimetics) with either low affinity or no affinity for DPP-IV. The discovery that DPP-IV can cleave GLP-1 in plasma [5] , whether exogenously administered or endogenously secreted [6, 7] , has opened the way for an alternative strategy for the treatment of type 2 diabetesthe development of inhibitors of DPP-IV [8] .
Although the rationale for the use of DPP-IV inhibitors is based upon their prolonging the actions of GLP-1, they also have other beneficial effects. DPP-IV inhibition blocks the inactivation of the other major incretin hormone, gastric inhibitory peptide (GIP). DPP-IV inhibitors therefore enhance concentrations of the active forms of both incretin hormones precisely when they are most needed (i.e. following meal ingestion), resulting in improved postprandial glucose control. Since the actions of both GLP-1 and GIP are glucose dependent, DPP-IV inhibition has the additional advantage that it carries a minimal risk of hypoglycaemia. Treatment with GLP-1 also lowers fasting glucose levels. Further support for this approach to therapy comes from the observations that glucose tolerance is improved in animals in which the enzyme has been genetically deleted [9] and in animals treated with DPP-IV inhibitors [10] . Clinical studies of type 2 diabetes show improved metabolic control, increased insulin secretion, reduced glucagon secretion, and favourable tolerability and safety during a treatment period of up to 1 year [11] [12] [13] . For example, the addition of a DPP-IV inhibitor to metformin resulted in a reduction in HbA 1 c of 1.1% relative to metformin plus placebo by the end of 1 year [13] (Fig. 1) .
DPP-IV is a widespread enzyme with the potential to cleave a large number of bioactive peptides other than GLP-1 and GIP [14] . The requisite for cleavage is that an alanine or a proline must be present as the second amino acid from the N-terminal end, in which case the two N-terminal amino acids are cleaved from the rest of the peptide. When this cleavage results in a loss of activity, as with GLP-1 and GIP, DPP-IV acts as an inactivation enzyme. However, it is possible that the effects of DPP-IV inhibition in diabetes are mediated by the inhibition of bioactive peptides other than GLP-1. One puzzling finding might support this: in patients with type 2 diabetes, concentrations of active GLP-1 after meal ingestion are doubled by DPP-IV inhibition (compared with placebo), and glucose control improves [13] . In contrast, when similar increases in GLP-1 levels are pro-duced by exogenous infusion, these have little or no effect on insulin secretion or glucose levels [15] . This suggests that mediators other than GLP-1 may contribute to the therapeutic effect of DPP-IV inhibition. Alternatively, recent findings indicate that GLP-1 may work indirectly through activation of the autonomic nervous system [16] , an effect possibly mediated by local activation of afferent nerve terminals. If this proves to be an important mechanism, comparison of circulating levels of GLP-1 under different conditions becomes less relevant, since the key factor would be the local concentration of active GLP-1 in the vicinity of nerve terminals rather than the concentration in the circulation.
GIP is a substrate for DPP-IV and augments insulin secretion in a glucose-dependent manner [2] . It is therefore a potential mediator of the effects of DPP-IV inhibition. A possible role is suggested by studies showing that DPP-IV inhibitors have no effect on acute glucose tolerance in mice with a double genetic deletion of GLP-1 receptors and GIP receptors, whereas they are still effective in mice with a genetic deletion of GLP-1 receptors alone [17] . Although GIP contributes to glucose tolerance during DPP-IV inhibition under normal conditions, this incretin is probably less important in mediating the actions of DPP-IV inhibitors in human diabetes. This is because GIP has little or no effect in this situation, possibly due to the downregulation of its receptors [15] .
Neuropeptides may contribute to the actions of DPP-IV inhibitors in diabetes. These are biologically active peptides that are localised to islet nerve terminals and function as neurotransmitters; some may be substrates for DPP-IV [14] . Neuropeptides that are stored in islet nerve terminals and affect islet function would be of particular relevance in this regard, and the islet autonomic nervous system is indeed sometimes overlooked as an important regulator of islet function [18] . One neuropeptide of potential importance is pituitary adenylate cyclase-activating peptide (PACAP), which is localised to islet nerves and has several actions relevant to glucose homeostasis [19] . For example, PACAP is a powerful stimulator of insulin secretion and may, like GLP-1, be of importance for islet mass. PACAP may play a leading role in contributing to the prandial, neurally dependent cephalic phase of insulin secretion. Furthermore, it enhances glucose uptake in adipocytes and augments the antilipolytic action of insulin [20, 21] , and its administration lowers circulating glucose in animal models of diabetes [22] . Since PACAP is also a substrate for DPP-IV [23, 24] , it is reasonable to speculate that this neuropeptide may contribute to the therapeutic benefits of DPP-IV inhibition. A recent animal study provided indirect evidence for this by demonstrating that PACAP-induced insulin secretion increased following inhibition of DPP-IV by valine pyrrolidide [25] . However, it is not yet known whether neuropeptides such as PACAP are substrates of DPP-IV in humans under physiological conditions, and this remains a weakness in this line of argument. We still lack the techniques required to conclusively determine the importance of PACAP in the regulation of islet function and glucose homeostasis in humans.
This issue of Diabetologia contains two sides of a debate concerning potential mediators of the therapeutic effects of DPP-IV inhibition. Nauck and El-Ouaghlidi present five arguments suggesting that GLP-1 is not the only-or at least not the major-mediator of the glucose-lowering actions of DPP-IV [26] . Holst and Deacon acknowledge these arguments, but maintain that current evidence nonetheless supports a dominant role for GLP-1 [27] . This debate highlights the importance of establishing the detailed mechanisms underlying the beneficial effects of DPP-IV inhibition in type 2 diabetes. Further studies exploring the mechanisms underlying the improvement in metabolic control following DPP-IV inhibition are clearly warranted, and could help optimise this promising approach to therapy. For example, second-generation DPP-IV inhibitors might selectively target bioactive peptides that regulate islet function, although novel techniques allowing measurement of neuropeptides and their actions at the tissue level in humans would be needed to make this possible. In the interim, we should welcome the new knowledge and potential clinical benefits afforded by these new agents. 
